• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Inhibition of the immunoproteasome may improve graft acceptance [PreClinical]

byCorinne FoleyandJessica Lau
February 11, 2017
in Cardiology, Preclinical, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. A targeted immunoproteasome inhibitor, DPLG3, was found to have high selectivity for the immune cell proteasome and was not toxic to other cell types.

2. When administered after a heart transplant in mice, DPLG3 allowed for minimal graft rejection through a decrease in T cell activation.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Organ transplants typically require the recipient to continue taking immunosuppressive medications to prevent rejection of the graft. However, the toxicity of these medications necessitates a safer option for transplant recipients. Researchers in this study synthesized DPLG3, a molecule that was modeled after a currently prescribed proteasome inhibitor and had selectivity to a subunit of the immunoproteasome.

When tested in vitro, DPLG3 selectively inhibited the β5i immunoproteasome subunit in a lymphoma cell line and did not affect other immunoproteasomes or cell types. The compound was found to decrease T cell proliferation in response to alloantigens. In a mouse model of skin transplantation, treatment with DPLG3 decreased the production of inflammatory cytokines and increased the expression of coinhibitory molecules by T cells. Next, DPLG3 was administered to mice that received a heart transplant from a mouse of another strain. These mice survived longer than the recipients that did not receive the compound, and there were few signs of rejection histologically. In addition, there were fewer effector T cells in the spleen, indicating the inhibition of an immune response. Overall, there was less lymphocyte infiltration and a decrease in T cell activation and proliferation compared to mice not treated with DPLG3. This study demonstrated that the synthesis of a selective proteasome inhibitor to prevent immune response to allografts could potentially allow for a safer and more efficacious medication for transplant recipients.

Click to read the study in PNAS

RELATED REPORTS

Genetically modified porcine-to-human cardiac xenograft failure

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

Relevant Reading: Proteasome inhibition suppresses essential immune functions of human CD4+ T cells

In-Depth [animal study]: An N,C-capped dipeptide, DPLG3, was synthesized to selectively bind to β5i 99,000-fold higher than β5c, a selectivity significantly greater than the currently available proteasome inhibitor. In vitro, DPLG3 inhibited β5i activity in Karpas lymphoma cells, while it had no effect on β5c activity in HepG2 human hepatoma cells. DPLG3 was not cytotoxic to human peripheral blood mononuclear cells. When T cells were isolated from the spleen of mice and treated with increasing concentrations of DPLG3, there was a concentration-dependent decrease in proliferation assessed using 3H-thymidine incorporation (p<0.05). A similar result was seen when mice that received a skin allograft were treated with 25 mg/kg of the compound. Their immune cells showed reduced proliferation in response to alloantigen, increased gene expression of coinhibitory molecules such as CTLA4 and BTLA, as well as a decrease in the pro-inflammatory cytokines IL-2 and IL-17 (p<0.05).

The efficacy of DPLG3 was then tested on C57BL/6 mice that were allografted with hearts from BALB/c mice. The recipient mice were then given 25 mg/kg DPLG3 each day for 14 days after receiving the transplant. These mice were found to have a significant decrease in the percentage of T cells in the spleen (p<0.05), demonstrating a lack of immune activation. In addition, the splenocytes demonstrated reduced responsiveness to alloimmune stimuli and there was a significant decrease in histologic signs of graft rejection. The treated mice had overall longer graft survival, with no death seen with 2 weeks of treatment with DPLG3 and a single dose of 25 µg CTLA4 Ig.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: transplant
Previous Post

Intensive blood pressure control not linked with mobility/gait speed in elderly adults

Next Post

Ultrasound-guided microwave ablation may be effective in severe secondary hyperparathyroidism

RelatedReports

Image-guided percutaneous drainage of pericardial effusions is safe and effective
Cardiology

Genetically modified porcine-to-human cardiac xenograft failure

July 11, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection
StudyGraphics

#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

January 5, 2022
#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years
StudyGraphics

#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years

October 29, 2021
Next Post
Ultrasound-guided microwave ablation may be effective in severe secondary hyperparathyroidism

Ultrasound-guided microwave ablation may be effective in severe secondary hyperparathyroidism

Smoking during pregnancy associated with aerobic fitness of children

2 Minute Medicine Rewind February 13, 2017

Stochastic resonance stimulation may decrease apnea of prematurity

Clinical prediction score predicts risk of neonatal rebound hyperbilirubinemia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial
  • Genetic risk for hemochromatosis associated with abnormal iron deposition localized to motor circuits of the brain
  • Graded sensorimotor retraining may improve chronic lower back pain compared to sham procedure: The RESOLVE randomized clinical trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.